|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-3-16
|
|
pubmed:abstractText |
Steroid refractory graft versus host disease (GVHD) presents a significant therapeutic challenge due to the limited efficacy and safety of second-line treatments. Three patients with extensively pretreated, refractory GVHD were treated with a targeted anti-T-cell agent, alefacept, and demonstrated rapid and clinically significant improvement in their GVHD, facilitating tapering of corticosteroids. The pathological and immunohistochemical findings of GVHD also improved, validating our clinical impression. These preliminary findings indicate that alefacept may have beneficial activity in GVHD warranting further study.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0954-6634
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
13-8
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:17365261-Adrenal Cortex Hormones,
pubmed-meshheading:17365261-Adult,
pubmed-meshheading:17365261-Aged,
pubmed-meshheading:17365261-Antigens, CD2,
pubmed-meshheading:17365261-Bone Marrow Transplantation,
pubmed-meshheading:17365261-Dermatologic Agents,
pubmed-meshheading:17365261-Female,
pubmed-meshheading:17365261-Graft vs Host Disease,
pubmed-meshheading:17365261-Humans,
pubmed-meshheading:17365261-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:17365261-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:17365261-Lymphoma, Non-Hodgkin,
pubmed-meshheading:17365261-Male,
pubmed-meshheading:17365261-Middle Aged,
pubmed-meshheading:17365261-Recombinant Fusion Proteins,
pubmed-meshheading:17365261-T-Lymphocytes,
pubmed-meshheading:17365261-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity.
|
|
pubmed:affiliation |
Bone Marrow Transplantation Program, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural,
Validation Studies
|
